Mobocertinib Succinate is Used for treating non-small cell lung cancer patients with EGFR exon 20 insertion mutations whose disease has progressed after platinum-based chemotherapy. It was first introduced by Takeda Pharmaceuticals Usa Inc in its drug Exkivity on Sep 15, 2021.

Mobocertinib Succinate Patents

Given below is the list of patents protecting Mobocertinib Succinate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Exkivity	US10227342	Heteroaryl compounds for kinase inhibition	May 13, 2035	Takeda Pharms Usa
Exkivity	US9796712	Heteroaryl compounds for kinase inhibition	May 13, 2035	Takeda Pharms Usa

Add above patents to watchlist

Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳